Clover Health PPO Plans Land 5-Star CMS Rating, Unlocking Year-Round Enrollment
CLOV has more than doubled off its 52-week low of $1.58.
Summary
CMS awarded Clover Health's PPO Medicare Advantage plans a 5-Star rating for 2027, up from 4.5 Stars when all 20 contested measures are included. The rating affects payment year 2028 and allows year-round enrollment for beneficiaries, a meaningful competitive advantage. Clover's HMO plan received 4.5 Stars. The company also reported a HEDIS score of 4.82 out of 5, ranking #1 among non-SNP PPO plans with over 2,000 members. This follows a 48% year-over-year membership surge to over 157,000 members in the first half of 2026, with ~98% in PPO plans. The 5-Star designation strengthens Clover's ability to attract and retain members and reinvest in benefits, supporting its growth trajectory.
At the time of this announcement, CLOV was trading at $5.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $1.58 to $5.59. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.